Company Encyclopedia
View More
name
FOXO Tech
FOXO.US
FOXO Technologies Inc. operates as a healthcare services and technology company in the United States. The company operates through two segments: Healthcare and Labs and Life. The company offers behavioural health; ancillary, including laboratory, radiology, respiratory, and pharmacy; insurance; and other services.
2.724 T
FOXO.USMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
C
Application SoftwareIndustry
Industry Ranking185/254
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-1727.27%E
    • Profit Margin-66.46%E
    • Gross Margin41.74%B
  • Growth ScoreA
    • Revenue YoY1000.04%A
    • Net Profit YoY-120.81%E
    • Total Assets YoY22.08%A
    • Net Assets YoY214.71%A
  • Cash ScoreB
    • Cash Flow Margin-63.49%D
    • OCF YoY1000.04%A
  • Operating ScoreD
    • Turnover0.31D
  • Debt ScoreD
    • Gearing Ratio61.35%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FOXO Technologies Inc. Files Information Statement Detailing Authorized Corporate Actions

    FOXO Technologies Inc. has filed an information statement detailing corporate actions authorized by its shareholders on December 16, 2025. The actions received approval from the Board of Directors and a majority shareholder. The full filing is accessible via the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    FOXO
    0.00%
    Reuters·
    US
    FOXO
    0.00%

    FOXO Technologies Expands Share Authorization and Preferred Terms

    FOXO Technologies has amended the terms of its Series B and C preferred stock, revising the conversion price formula and removing the mandatory conversion provision. Majority stockholder Rennova Health approved an increase in authorized Class A common shares and preferred shares, enhancing FOXO's capital-raising flexibility. Despite these changes, FOXO faces financial challenges, with a low stock score due to net losses, high debt, and negative cash flows. The company is controlled by Rennova Health, holding 98.6% voting rights.

    Tip Ranks·
    US
    FOXO
    0.00%
    Tip Ranks·
    US
    FOXO
    0.00%

    FOXO Technologies Inc. approved board re-election and bylaw amendments

    FOXO Technologies Inc. held a meeting on December 16, 2025, where shareholders approved amendments to the Certificate of Incorporation, revised conversion price terms for Series B and C Preferred Stock, re-elected board members, and ratified Kreit & Chiu CPA LLP as the independent accounting firm for 2025.

    Reuters·
    US
    FOXO
    0.00%
    Reuters·
    US
    FOXO
    0.00%

    FOXO Technologies Inc. Files Draft Information Statement Outlining Board-Authorized Corporate Actions

    FOXO Technologies Inc. announced that its shareholders, led by majority shareholder Rennova Health, Inc., have authorized certain corporate actions as of December 16, 2025. These actions were approved through written consent and the full filing is available via EDGAR. The announcement was made on December 19, 2025.

    Reuters·
    US
    FOXO
    0.00%
    Reuters·
    US
    FOXO
    0.00%

    FOXO Technologies Inc. Announces Plans to Pursue Growth Through Healthcare Sector Acquisitions, Expansion of Operating Subsidiaries, and Investment in Pharmaceutical Services Business

    FOXO Technologies Inc. plans to grow by acquiring healthcare sector businesses, expanding subsidiaries, and investing in pharmaceutical services. It formed FOXO Acquisition Corporation for future acquisitions and created Series E Preferred Stock to support these activities. The company aims to expand Vector BioSource, Inc. and seeks more acquisition opportunities in healthcare. This strategy was announced via EDGAR on December 16, 2025.

    Reuters·
    US
    FOXO
    0.00%
    Reuters·
    US
    FOXO
    0.00%
    © 2025 Longbridge｜Disclaimer